Butyrate, a short-chain fatty acid from gut bacteria, functions similarly to HDAC inhibitor drugs used in cancer therapy. This provides a scientific mechanism for how diet impacts myeloma, revealing its role in anti-tumor and anti-inflammatory pathways.
For patients with pre-cancerous conditions like MGUS and smoldering myeloma, diet can significantly influence their progression to an active myeloma diagnosis. This positions dietary intervention not just as supportive care but as a key tool for mitigating disease progression.
A common multiple myeloma treatment, autologous stem cell transplant, causes a significant decrease in beneficial, butyrate-producing gut bacteria. This treatment-induced change is directly associated with inferior progression-free survival, revealing a paradoxical negative effect of a standard therapy.